Wechselwirkungen · Lixiana
Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-127803 · Präparat HOS-096471
Edoxaban is a substrate for the efflux transporter P-gp. In pharmacokinetic (PK) studies, concomitant administration of edoxaban with the P-gp inhibitors ciclosporin, dronedarone, erythromycin, ketoconazole, quinidine, or verapamil resulted in increased plasma concentrations of edoxaban. Concomitant use of edoxaban with ciclosporin, dronedarone, erythromycin, or ketoconazole requires dose reduction to 30 mg once daily. Concomitant use of edoxaban with quinidine, verapamil, or amiodarone does not require dose reduction based on clinical data (see section 4.2). The use of edoxaban with other P-gp inhibitors including human immunodeficiency virus (HIV) protease inhibitors has not been studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) protease (HOS-085623) ketoconazole (HOS-084513) quinidine (HOS-085593) erythromycin (HOS-084514) amiodarone (HOS-085596) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T13:11:00Z · SHA-256 5fd1fde6f72bf5d3892ddc2d35b116dd396f6657ffdfad7faca24bdcd927d334 · Passage 6a74087b198ddb5b29fb7a742e89d3cad69035714c3241bb8d7c59b44124da45 · Zeichen 260–959 im Abschnitt